Auris Medical Announces 20-F Filing
14 Março 2019 - 10:48PM
March 14, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a
clinical-stage company dedicated to developing therapeutics that
address important unmet medical needs in neurotology and central
nervous system disorders, announced today that it has filed its
Annual Report on Form 20-F for the year ended December 31, 2018,
with the U.S. Securities and Exchange Commission. A copy of the
Annual Report available in the Investor Relations section of the
Company's website www.aurismedical.com as well as on the
SEC's website at www.sec.gov. Upon request, Auris Medical will
send a copy of the Annual Report to any requesting shareholder.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to
developing therapeutics that address important unmet medical needs
in neurotology and central nervous system disorders. The company is
focused on the development of intranasal betahistine for the
treatment of vertigo (AM-125) and for the treatment of
antipsychotic-induced weight gain and somnolence (AM-201). These
projects have gone through two Phase 1 trials and will move into
proof-of-concept studies in 2019. In addition Auris Medical has two
Phase 3 programs under development: Sonsuvi® (AM-111) for
acute inner ear hearing loss and Keyzilen® (AM-101) for acute
inner ear tinnitus. The Company was founded in 2003 and is
headquartered in Zug, Switzerland. The shares of Auris Medical
Holding AG trade on the NASDAQ Capital Market under the symbol
"EARS."
Forward-looking Statements
This press release may contain statements that constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Forward-looking statements are statements
other than historical facts and may include statements that address
future operating, financial or business performance or Auris
Medical's strategies or expectations. In some cases, you can
identify these statements by forward-looking words such as "may,"
"might," "will," "should," "expects," "plans," "anticipates,"
"believes," "estimates," "predicts," "projects," "potential,"
"outlook" or "continue," or the negative of these terms and other
comparable terminology. Forward-looking statements are based on
management's current expectations and beliefs and involve
significant risks and uncertainties that could cause actual
results, developments and business decisions to differ materially
from those contemplated by these statements. These risks and
uncertainties include, but are not limited to, Auris Medical's need
for and ability to raise substantial additional funding to continue
the development of its product candidates, the timing and conduct
of clinical trials of Auris Medical's product candidates and that
such trials will not meet its endpoints , the clinical utility of
Auris Medical's product candidates, the timing or likelihood of
regulatory filings and approvals, Auris Medical's intellectual
property position and Auris Medical's financial position, including
the impact of any future acquisitions, dispositions, partnerships,
license transactions or changes to Auris Medical's capital
structure, including future securities offerings. These risks and
uncertainties also include, but are not limited to, those described
under the caption "Risk Factors" in Auris Medical's Annual Report
on Form 20-F for the year ended December 31, 2018 and future
filings with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made,
and Auris Medical does not undertake any obligation to update them
in light of new information, future developments or otherwise,
except as may be required under applicable law. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
Investor contact: Joseph
Green / Andrew Gibson Edison Advisors for Auris
Medical 646-653-7030 / 7719
jgreen@edisongroup.com / agibson@edisongroup.com
or investors@aurismedical.com
Auris Medical (NASDAQ:EARS)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Auris Medical (NASDAQ:EARS)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024